Assessment of Lipophilic vs. Hydrophilic Statin Therapy in Acute Myocardial Infarction.

Link to article at PubMed

Related Articles

Assessment of Lipophilic vs. Hydrophilic Statin Therapy in Acute Myocardial Infarction.

Circ J. 2014 Nov 12;

Authors: Izawa A, Kashima Y, Miura T, Ebisawa S, Kitabayashi H, Yamamoto H, Sakurai S, Kagoshima M, Tomita T, Miyashita Y, Koyama J, Ikeda U

Background:Statins reduce the incidence of cardiovascular events, but no randomized trial has investigated the best statins for secondary prevention. We compared the efficacy of hydrophilic pravastatin with that of lipophilic atorvastatin in patients with acute myocardial infarction (AMI).Methods and Results:A prospective, multicenter study enrolled 508 patients (410 men; mean age, 66.0±11.6 years) with AMI who were randomly assigned to atorvastatin (n=255) or pravastatin (n=253). The target control level of low-density lipoprotein cholesterol (LDL-C) was <100 mg/dl, and patients were followed for 2 years. The primary endpoint was the composite of death due to any cause, non-fatal myocardial infarction, non-fatal stroke, unstable angina or congestive heart failure requiring hospital admission, or any type of coronary revascularization. The primary endpoint occurred in 77 patients (30.4%) and in 80 patients (31.4%) in the pravastatin and atorvastatin groups, respectively (hazard ratio, 1.181; 95% confidence interval: 0.862-1.619; P=0.299), whereas greater reductions in serum total cholesterol and LDL-C were achieved in the atorvastatin group (P<0.001 for each). Changes in hemoglobin A1c, brain natriuretic peptide, and creatinine were not significant between the 2 regimens, and safety and treatment adherence were similar.Conclusions:On 2-year comparison of hydrophilic and lipophilic statins there was no significant difference in prevention of secondary cardiovascular outcome.

PMID: 25392071 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published. Required fields are marked *